News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Aventis Pharma Obtains Additional Approval for Taxoid Antitumor Agent TAXOTERE Injection
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Tokyo (JCN) - Aventis Pharma of the sanofi-aventis Group announced on August 19 that it has obtained additional approval for TAXOTERE Injection, its proprietary taxoid antitumor agent, from the Ministry of Health, Labor and Welfare as of August 18.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Sanofi US
Sanofi (France)
MORE ON THIS TOPIC
FDA
Makary Eyes ‘America-First’ User Fee Structure as Renewal Negotiations Approach
November 19, 2025
·
2 min read
·
Tristan Manalac
Podcast
Billions More in M&A, Another Bidding War and More FDA Drama
November 19, 2025
·
1 min read
·
Heather McKenzie
Approvals
Arrowhead Secures Maiden Approval, First FDA Nod for Rare Genetic Metabolic Disorder
November 18, 2025
·
2 min read
·
Heather McKenzie
Regulatory
FDA Imposes Boxed Warning, Narrows Patient Pool for Sarepta’s Duchenne Gene Therapy Elevidys
November 17, 2025
·
1 min read
·
Tristan Manalac